This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Anticholinesterases in the treatment of myasthenia gravis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Anticholinesterase compounds have traditionally been the mainstay of treatment for myasthenic patients e.g. pyridostigmine.

Common side effects include pupillary constriction, colic, diarrhoea, and increased salivation, sweating, lacrimation, and bronchial secretions. Adverse effects of these drugs - colic, diarrhoea - can usually be controlled by propantheline 15mg TDS (1).

The main problem inherent with symptomatic treatment is the ease with which the patient may pass from a myasthenic block and weakness sensitive to anticholinesterase, to a depolarisation block resultant from excessive acetylcholine at the motor end plate due to excess of the cholinesterase inhibitor.

In this scenario, further administration of the drug may be disastrous with possible respiratory paralysis. The resultant cholinergic crisis is managed by control of the airway and ventilation, administration of atropine and withdrawal of the drug. Immunosuppression or plasmapheresis may be required.

Spontaneous remissions may occur in 20% of patients treated with anticholinesterases alone.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.